Crohn’s & Colitis Congress™

Sessions Speakers Exhibitors Floor Plan Buzz
Search

Sessions (15)

P204 - ABILITY OF THERAPEUTIC TREATMENT TO AMELIORATE THE PRO-COLITOGENIC EFFECTS OF IL-15 DURING COLITIS

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking

Speaker(s): Marlies Meisel
Dysregulated host-microbial interactions leading to an imbalance between harmful and protective intestinal bacteria (dysbiosis) is largely responsi... More...

P205 - ALGINATE OLIGOMERS, A POTENTIAL ADJUVANT IN THE TREATMENT OF FISTULIZING CROHN’S DISEASE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking

Speaker(s): Philip Rye
Background: OligoG is a low mol. wt. alginate oligosaccharide (Mn 3200g/mol) that disrupts bacterial biofilm, potentiates antibiotics, reconditions... More...

P206 - ASSESSING THE COST-EFFECTIVENESS OF EPSTEIN-BARR VIRUS SCREENING IN YOUNG MEN INITIATING COMBINATION THERAPY WITH INFLIXIMAB AND AZATHIOPRINE FOR CROHN’S DISEASE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking

Speaker(s): Frank Scott
Introduction: Primary Epstein Barr virus (EBV) infection is associated with developing hemophagocytic lymphohistiocytosis (HLH) with azathioprine u... More...

P207 - CLINICAL PREDICTORS OF RESPONSE TO VEDOLIZUMAB TREATMENT IN CROHN’S DISEASE

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking

Speaker(s): Adam Dhedhi
Background: Vedolizumab (VDZ) is a monoclonal antibody to alpha4 beta7 integrin that is approved as first line therapy for Crohn’s Disease (C... More...

P208 - COMPLIANCE OF PREVENTATIVE HEALTH CARE MEASURES IN INFLAMMATORY BOWEL DISEASE: A QUALITY IMPROVEMENT PROJECT (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking, Poster Session

Speaker(s): Lynsey Maciolek
Introduction Prior studies have shown that patients with inflammatory bowel disease do not receive preventative measures as compared to the general... More...

P209 - EPIDEMIOLOGY OF NON-MELANOMA SKIN CANCERS IN HOSPITALIZED PATIENTS OF INFLAMMATORY BOWEL DISEASE IN USA: INSIGHTS FROM NATIONAL INPATIENT SURVEY (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking

Speaker(s): Zubair Khan
Introduction: Non-melanoma skin cancer (NMSC) is among the most common malignancies in the United States. Patients with inflammatory bowel disease ... More...

P210 - GASTROINTESTINAL SYMPTOMS ARE COMMON IN U.S. PATIENTS WITH MODERATE-SEVERE PSORIASIS (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking

Speaker(s): Steven Feldman
Intro/Background: Patients with moderate-to-severe plaque psoriasis (PsO) are at increased risk of developing inflammatory bowel disease (IBD). Aim... More...

P211 - IMPACT OF OBESITY ON FUTURE IBD-RELATED COMPLICATIONS IN A POPULATION-BASED COHORT OF CROHN’S DISEASE (CD) AND ULCERATIVE COLITIS (UC) PATIENTS (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking

Speaker(s): Amanda Lynn
Introduction: Obesity is known to increase morbidity and mortality in a number of chronic conditions. As a proposed risk factor for adverse outcome... More...

P212 - NOVEL ROLE OF INTESTINAL GOBLET CELLS IN INDUCTION OF TOLERANCE AND PROMOTING STABILITY OF REGULATORY T CELLS (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking

Speaker(s): Devesha Kulkarni
Background: Mucosal tolerance towards luminal antigens is a process fundamental to intestinal homeostasis, the breakdown of which results in onset ... More...

P213 - THE IMPACT OF SMOKING STATUS ON MORTALITY AND OTHER OUTCOMES IN HOSPITALIZED PATIENTS OF INFLAMMATORY BOWEL DISEASE IN UNITED STATES: “THE SMOKER’S PARADOX” (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking

Speaker(s): Zubair Khan
Introduction: Ulcerative colitis (UC) and Crohn’s disease (CD) result from genetic and environmental factors. Never smoking and formerly smok... More...

P214 - TRENDS IN THE INCIDENCE AND OUTCOMES OF CHOLANGITIS IN HOSPITALIZED PATIENTS OF ULCERATIVE COLITIS: NATIONWIDE ANALYSIS 2002-2014 (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking

Speaker(s): Zubair Khan
Introduction: Most of the cholangitis cases in inflammatory bowel disease (IBD) are attributable to primary sclerosing cholangitis (PSC) and less c... More...

P215 - UNDERSTANDING PHENOTYPIC DISTINCTIONS IN SUB-POPULATIONS OF VERY EARLY ONSET- INFLAMMATORY BOWEL DISEASE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking

Speaker(s): Judith Kelsen
Background: IBD diagnosed 5 can present with a distinct and more severe phenotype than older–onset IBD. We aim to compare the clinical charac... More...

P216 - WHAT IS THE RATE OF CHRONIC OPIOID USE AND HOW IT IMPACTS HEALTHCARE UTILIZATION WITHIN AN IBD CLINIC POPULATION

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Late-Breaking

Speaker(s): Bill Hacker
Background: Opioid analgesics are frequently used to manage chronic abdominal pain in inflammatory bowel disease (IBD). We sought to quantify opioi... More...

29 - METHOTREXATE IS NOT SUPERIOR TO PLACEBO IN MAINTAINING REMISSION IN PATIENTS WITH ULCERATIVE COLITIS – THE MERIT-UC STUDY (Room Pinyon 4/5)

20 Jan 18
9:55 AM - 10:02 AM

Tracks: Late-Breaking

Speaker(s): James Lewis MD, MSCE, AGAF
Background In the METEOR trial, methotrexate (MTX) induced steroid free clinical remission but not endoscopic healing in a significantly higher per... More...

30 - USTEKINUMAB LEADS TO CLINICAL RESPONSE AMONG PATIENTS WITH CROHN’S DISEASE OF THE POUCH AND CHRONIC ANTIBIOTIC DEPENDENT POUCHITIS (Room Pinyon 04/05)

20 Jan 18
10:02 AM - 10:09 AM

Tracks: Late-Breaking

Speaker(s): Kimberly Weaver
Background: Little is known regarding the efficacy of ustekinumab in the treatment of pouchitis and Crohn’s Disease (CD) of the pouch in pati... More...